Personalis

188 articles with Personalis

• Personalis Announces Four Abstracts Accepted for Presentation at AACR Annual Meeting 2023

  3/22/2023

  Personalis, Inc. (Nasdaq: PSNL) today announced it is presenting new research data as scientific posters at the American Association for Cancer Research (AACR) Annual Meeting 2023, which convenes from April 14-19, 2023 in Orlando, Florida.

• Personalis Selected for Clinical Research After Successful Evaluation of Whole Genome-Based Molecular Residual Disease Assay

  3/7/2023

  Personalis, Inc. (Nasdaq: PSNL) today announced it will continue its collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) to explore ultra-sensitive molecular residual disease (MRD) measurement, including clinically relevant and personalized variant tracking, for clinical research and drug development.

• Personalis Appoints Christopher Hall as Chief Executive Officer

  3/2/2023

  Personalis, Inc., a leader in advanced genomics for precision oncology, announced that its Board of Directors has appointed Christopher Hall as Chief Executive Officer and a member of the Board, effective immediately, in addition to his role as President.

• Personalis Reports Fourth Quarter and Full Year 2022 Financial Results

  2/23/2023

  Personalis, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided recent business highlights.

• Personalis to Announce Fourth Quarter and Full Year 2022 Financial Results

  2/9/2023

  Personalis, Inc., a leader in advanced genomics for precision oncology, announced that it will release its fourth quarter and full year 2022 financial results on Thursday, February 23, 2023.

• Personalis to Participate at Upcoming Investor Conferences - February 06, 2023

  2/6/2023

  Personalis, Inc., a leader in advanced genomics for cancer, announced that its management team will participate at the following investor conferences.

• Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials

  2/3/2023

  Personalis, Inc. and Moderna, Inc. today announced the companies have signed a new agreement to continue using the Personalis NeXT Platform® as part of upcoming clinical studies evaluating mRNA-4157/V940.

• Personalis Reports Preliminary Fourth Quarter and Full Year 2022 Revenue

  1/4/2023

  Personalis, Inc., a leader in advanced genomics for precision oncology, reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2022.

• Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 16, 2022

  12/16/2022

  Personalis, Inc. announced that the Compensation Committee of its Board of Directors granted, between the dates of December 5, 2022 and December 16, 2022, non-qualified stock options to purchase an aggregate of 35,000 shares of its common stock and restricted stock units covering an aggregate of 42,100 shares of its common stock to three new employees under Personalis’ 2020 Inducement Plan.

• Personalis Announces CEO Retirement and Transition

  12/14/2022

  Personalis, Inc., a leader in advanced genomics for precision oncology, announced that John West, co-founder, CEO and member of the board of directors of Personalis, notified the Company of his decision to retire as CEO and a director at the end of the calendar year.

• Personalis Cancer Assay NeXT Personal Ranks #1 on The Scientist’s Top 10 Innovations of 2022

  12/12/2022

  Personalis, Inc. today announced its NeXT Personal ® cancer assay earned the top spot on The Scientist’s Top 10 Innovations of 2022 list.

• Personalis and UCSF to Study Clinical Utility of ctDNA for Treatment Response in Colorectal Cancer

  11/30/2022

  Personalis, Inc. (Nasdaq: PSNL) today announced a collaboration with UC San Francisco (UCSF) that will deploy a personalized liquid biopsy-based research use only (RUO) assay for a study of patients with colorectal cancer.

• Personalis to Present at the 34th Annual Piper Sandler Healthcare Conference

  11/21/2022

  Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 34th Annual Piper Sandler Healthcare Conference on Wednesday, November 30, 2022 at 1:30 p.m. Eastern Time in New York, NY.

• Personalis Presents Data from New Platform Features at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

  11/7/2022

  Personalis, Inc. (Nasdaq: PSNL) today announced that the company will share data resulting from expanded features of its NeXT Platform® at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, November 8-12 in Boston, with three abstracts that highlight advanced R&D applications of next-generation sequencing (NGS) in immuno-oncology.

• Personalis Grows Leadership Team with Appointment of Christopher Hall as Senior Vice President and Head, Diagnostics Business

  10/31/2022

  Personalis, Inc., a leader in advanced genomics for cancer, announced the appointment of Christopher Hall as SVP and Head, Diagnostics Business.

• Personalis to Announce Third Quarter 2022 Financial Results

  10/19/2022

  Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its third quarter 2022 financial results on Wednesday, November 2, 2022.

• Personalis Forms Research Collaboration to Better Predict Immunotherapy Response for Gastroesophageal Cancer

  10/4/2022

  Personalis, Inc. has joined with Duke University and Olink Proteomics AB to form a research collaboration to study the effects of immunotherapy on advanced gastroesophageal cancer.

• Personalis to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

  8/30/2022

  Personalis, Inc. announced that its management team will present at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022 at 1:30 p.m. Eastern Time in New York, NY. About Personalis Personalis, Inc. is a leader in advanced cancer genomics, enabling the next generation of precision cancer therapies and diagnostics.

• Personalis Adds New MRD Patent Covering the Combination of Tumor-Informed and Database-Derived Content to Patent Infringement Complaint Against Foresight Diagnostics

  8/17/2022

  Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today it has filed an amended complaint against Foresight Diagnostics.

• Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 16, 2022

  8/16/2022

  Personalis, Inc. announced that, effective on August 15, 2022, the Compensation Committee of its Board of Directors granted non-qualified stock options to purchase an aggregate of 70,000 shares of its common stock and restricted stock units covering an aggregate of 70,000 shares of its common stock to two new employees under Personalis’ 2020 Inducement Plan.